Statins and colorectal cancer risk: a longitudinal study

Area of Science:

• Epidemiology
• Pharmacology
• Oncology

Background:

• Conflicting evidence exists regarding the association between statin use and colorectal cancer (CRC) risk.
• Previous studies have employed diverse methodologies to mitigate bias, leading to varied findings.
• Investigating potential sex-based differences in this association is crucial for personalized risk assessment.

Purpose of the Study:

• To evaluate the association between statin initiation and colorectal cancer (CRC) incidence.
• To address confounding factors using multiple analytical approaches, including healthy user bias adjustment.
• To explore potential effect modification by sex in the statin-CRC relationship.

Main Methods:

• Retrospective cohort study utilizing the Emilia-Romagna, Italy healthcare database (2003-2010).
• Statin initiators were compared with glaucoma medication initiators to control for healthy user bias.
• Multivariable Cox regression and propensity score matching were employed to adjust for confounders and validate findings.

Main Results:

• Statin initiation was associated with a reduced CRC incidence (HR 0.79; 95% CI 0.69-0.90) after multivariable adjustment.
• A significant protective effect was observed in men (HR 0.77; 95% CI 0.67-0.88), but not in women (HR 0.96; 95% CI 0.82-1.1).
• Propensity score analysis yielded similar results, reinforcing the main findings.

Conclusions:

• Statin initiation demonstrated a reduced risk of colorectal cancer in men, but not in women, after adjusting for confounders.
• The findings suggest a sex-specific association between statin use and CRC risk.
• This study corroborates previous research indicating gender differences in the statin-CRC relationship, despite inherent limitations.